title: Advances in Pediatric Inflammatory Bowel Disease.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Maxwell
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Grossman
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000628:therapy*; D003424:Crohn Disease / Q000175:diagnosis / Q000628:therapy*; D004750:Enteral Nutrition; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000628:therapy; D000069285:Infliximab / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D012460:Sulfasalazine; D019804:Mesalamine; C543529:vedolizumab; D000069285:Infliximab; D000068879:Adalimumab; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate